Document:

Assignment of Invention

 Exhibit 10.2 
  
 ASSIGNMENT OF INTEREST 
  
 WHEREAS, W. KEITH R. WATSON, a citizen of United Kingdom residing in Rosarito Beach, Baja California, Mexico, has developed a new molecule, employing combinations of
fluorochemicals with suitable emulsifying agents, that is stable at room temperatures and possesses enhanced oxygen carrying capacity and overcomes the toxic reaction problem in the use of synthetic phospholipids in substitute blood when
fluorochemicals are used, therefore making it useful in the synthesis of artificial blood, 
  
 AND WHEREAS, this new molecule is being readied for patent application in Mexico, the United States, and world wide, 
  
 THEREFORE BE IT RESOLVED THAT, I do hereby assign to SINEQUONAN CORPORATION of New Jersey, all interests, rights, and ownership of this new molecule, and all improvements
made thereon, for Twelve Million Six Hundred & Eighty Thousand (12,680,000) shares of the stock of SINEQUONAN CORP., or not less that seventy-two (72%) per cent of the issued and outstanding stock after the above 12,680,000 shares are issued.

  
 EXECUTED THIS 19th DAY OF SEPTEMBER, 1990, in Rosarito Beach, Baja California,
Mexico. 
  

							
	 WITNESS:
	 	 /s/

	 	 SIGNED:
	 	 /s/

	 	 	 ROBERT LARSON
	 	 	 	 W. KEITH R. WATSONLicense Agreement

 Exhibit 10.3 
  
 LICENSE AGREEMENT 
  
 THIS AGREEMENT made and effective as of the date of last signing (herein the “Effective Date”) by and between SYNTHETIC BLOOD INTERNATIONAL,
INC., hating a principal place of business at 3189 Airway Avenue, Building C, Costa Mesa, CA 92626 (hereinafter “Company”), and CHILDREN’S HOSPITAL RESEARCH FOUNDATION an operating, division of Children’s Hospital Medical Center
(hereinafter “CHRF”), having a principal place of business at 3333 Burnet Avenue, Cincinnati, Ohio 45229-3039, TJSA. 
  
 INTRODUCTION 
  

	1.	WHEREAS, CHRF has developed and is continuing research in the area of Technology, as defined in Article 1.1 of this Agreement, and 

  

	2.	WHEREAS, Company desires to obtain certain rights in and to the Technology; and 

  

	3.	WHEREAS, Company has represented to CHRF, to induce CHRF to enter into this Agreement, that Company has the desire, expertise and knowledge to develop, produce, market and sell
Products and/or to us Processes and that it shall commit itself to a thorough, vigorous and diligent program of exploratory the Technology such that public utilization shall result therefrom; and 

  

	4.	WHEREAS, Company and CHRF mutually desire to formalize an agreement which delineates their respective rights and obligations with respect to the Technology, and

  

	5.	WHEREAS, CHRF is the lawful owner of the Technology and Know-how and has the right to grant the license as provided herein. 

  
 NOW, THEREFORE, in consideration of the mutual covenants and promises
contained in this Agreement and other good and valuable consideration, CHRF and Company agree as follows: 
  
 ARTICLE 1 - DEFINITIONS 
  
 In the terms defined and used herein, the singular shall include the plural and vice versa. Terms in this Agreement (other than names of parties and Article headings) which we set forth in upper case letters have the
meanings established for such terms in the succeeding paragraphs of this Article 1. 
  

	1.1	“Affiliate” mans any company, corporation of business which is at least fifty percent owned or controlled by Company, or which owns or controls at least fifty percent of
Company, or which together with Company is commonly owned or controlled by a third party who owns or controls at least fifty percent of each 

  

	1.2	“Effective Date” of this Agreement means the date of last signing. 

  

	1.3	“Field” means the continuous monitoring of blood glucose levels iii diabetes. 

	1.4	“Government” means the United States Government. 

  

	1.5	“Know-how” means the data and information embodied in the Technology. 

  

	1.6	“Improvement” means any modification of Product and/or Process made within the Term of this Agreement in the course of research supported by Company hereunder.

  

	1.7	“Patents” means any and all patent applications filed in any country of the world by or on behalf of CHRF claiming the Technology and/or any patents maturing from such
patent applications, specifically including United States Patents No. 4,458,686 entitled “Cutaneous Methods of Measuring Body Substances” and No. 4,680,268 and divisional patent No. 4,721,677 both entitled “Implantable Gas-Containing
Biosensor and Method for Measuring an Analyte Such as Glucose” and corresponding foreign patents No. 0215678 for the countries of Austria, Belgium, Switzerland, dance, United Kingdom, Italy; No. 1,284,454 For Canada; No. P3687871.5 for German
and No. 2638593 for Japan, Luxembourg, Netherlands and Sweden. 

  

	1.8	“Process” means any and all processes embodying the Technology, Know-how and/or the Patents. 

  

	1.9	“Product” means any and all products embodying the Technology, Know-how and/or the Patents. 

  

	1.10	“Technology” means Implantable glucose biosensor of CHRF as described and claimed in the Patents; and Improvement thereto. 

  

	1.11	“Term” means the period beginning on the Effective Date and extending to the expiration of the last to expire Patent, or for Fifteen (15) years, whichever is longer.

  

	1.12	“Territory” means the world. 

  
 ARTICLE 2 - LICENSE 
  

	2.1	CHRF hereby grants and agrees to grant to Company an exclusive license within the Territory, only in the Field, to make, have made, use, distribute and market Products and practice
the Processes under the Technology, the Know-how and/or the Patents. 

  

	2.2	The exclusive license specified in Paragraph 2.1 is subject to the rights of CHRF to utilize the Technology, the Know-how, the Processes and/or the Patents for the non-commercial
research purposes of CHRF. 

  

	2.3	The exclusive license specified in Paragraph 2.1 may be subject to certain rights of the Government if the Technology, the Know-how, and/or the Patents were created or invented in
the course of Government-funded research. Such rights may include, for example, a royalty-free license to the Government and the requirement that any Product produced for sale in the United States will be manufactured substantially in the United
States. 

  

 2 

 ARTICLE 3 - DUE DILIGENCE 
  

	3.1	Company shall use its best efforts to bring one or more Products or Processes to market through thorough, vigorous and diligent programs of research, development, testing and
marketing of the Technology and to continue active, diligent marketing efforts for one or more Products or Processes throughout the life of this Agreement. 

  

	3.2	Company’s failure to perform in accordance with any and all portions of Paragraphs 3.1 above shall be grounds for CHRF to terminate this agreement pursuant to Article 10.

  
 ARTICLE 4 - PATENTS AND PATENT COSTS

  

	4.1	CHRF shall retain title to the Technology, the Know-how and the Patents. 

  

	4.2	CHRF shall maintain Patents in the United States and in all foreign countries designated within Paragraph 1.7 herein. 

  

	4.3	Company agrees promptly to reimburse CHRF for its outside legal costs incurred under Paragraph 4.2. 

  

	4.4	Failure of Company to pay the amounts required under Paragraph 4.1 within thirty (30) days of the receipt of a written statement will be a breach of this Agreement.

  
 ARTICLE 5 - PAYMENTS 
  

	5.1	Upon execution of this Agreement, Company shall pay to CHRF a license fee (“License Fee”) of thirty-six thousand sixty-two dollars and thirteen cents ($36,062.13) within
thirty days (30) days of the Effective Date. 

  

	5.2	Company agrees to pay CHRF for all future patent maintenance and legal fees associated with the Patents within thirty (30) days of receipt of invoice from CHRF.

  

	5.3	In addition, Company agrees to issue to CHRF within thirty (30) days of the Effective Date, a certificate for fifteen thousand (15,000) shares of duly authorized common stock of
Company, subject to CHRF’s due diligence of Company and agreement on the value of said shares. 

  
 ARTICLE 6 - INFRINGEMENT 
  

	6.1	Each party shall promptly report in writing to the other party daring the Term of this Agreement any infringement or suspected infringement of any patent, or unauthorized use or
misappropriation of the Technology or Know-how by a third pasty of which it becomes aware, and shall provide the other party with all available evidence supporting said infringement, suspected infringement, suspected infringement or unauthorized use
or misappropriation. 

  

	6.2	Except as provided in Paragraph 6.3, Company shall have the right. to initiate an infringement suit or other appropriate action against any third party who at any time has

  

 3 

 infringed or is suspected of infringing any of the Patents or of using without proper authorization all
or any portion of the Technology or Know-how. Company shall give CHRF sufficient advance written notice of its intent to initiate such action and the reasons therefore, and shall provide CHRF with an opportunity to make suggestions and comments
regarding such action. Company shall keep CHRF promptly informed of the status of any such action. Company shall have the sole and exclusive right to select counsel for and shall pay all expenses of such action. CHRF shall offer reasonable
assistance to Company ire connection there-with at no charge to Company except for reimbursement of reasonable out-of-pocket expenses. Company may settle any such action without prior approval of CHRF. CHRF shall receive ten percent (10%) of all
damages, profits or awards of whatever nature recovered from such action under this Agreement after Company has been compensated for its costs in handling such action. 
  

	6.3	In the event that Company does not within six (6) months (a) secure cessation of the infringement, or (b) enter suit against the infringer, CHRF shall thereafter have the right but
not the obligation to convert Company’s exclusive license hereunder to a non-exclusive license, and/or to take action against the infringer at CHRF’s own expense. Company shall offer reasonable assistance to CHRF in connection with such
action at no charge to CHRF except for the reimbursement of reasonable out-of-pocket expenses. Any damages, profits or awards of whatever nature recovered from. such action shall belong solely to CHRF. 

  
 ARTICLE 7 - WARRANTY DISCLAIMER 
  

	7.1	Nothing in this Agreement shall be construed as: 

  

	 	(a)	A warranty or representation by CHRF as to the validity or scope of any Patent.; 

  

	 	(b)	A warranty or representation that anything made, used, sole, or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of patents,
copyrights and/or trademarks of third parties; 

  

	 	(c)	An obligation of CHRF to bring or prosecute actions or suits against third parties for infringement; 

  

	 	(d)	Conferring rights to use in advertising, publicity or otherwise any trademark or the name of CHRF or the Children’s Hospital Medical Center of Cincinnati, Ohio; or

  

	 	(e)	Granting by implication, estoppel or otherwise any licenses under patents of CHRF other than Patents, regardless of whether such other patents are dominant of or subordinate to any
Patent. 

  

	7.2	Except as expressly set forth in this Agreement, CHRF MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND ASSUMES NO RESPONSIBILITIES
WHATEVER WITH RESPECT TO THE USE, SALE OR OTHER DISPOSITION BY COMPANY OR ITS VENDEES OR OTHER TRANSFEREES OF PRODUCTS INCORPORATING 

  

 4 

 OR MADE BY USE OF INVENTIONS LICENSED UNDER THIS AGREEMENT OR INFORMATION, IF ANY, FURNISHED UNDER THIS
AGREEMENT. SUCH INVENTIONS AND INFORMATION ARE PROVIDED AS IS, WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. 
  
 ARTICLE 8 - NOTICES 
  

	8.1	Communications to Company concerning this Agreement should be addressed to: 

  

Synthetic Blood International, Inc. 
 3189 Airway Avenue, Building C 
 Costa Mesa, CA 92626 
 ATTN: Robert W. Nicara 
               President 
  

	8.2	Communications to CHRF concerning this Agreement should be addressed to: 

  
 Director, Technology Transfer 
 Children’s Hospital Research Foundation 
 3333 Burnet Avenue 
 Cincinnati, Ohio 45229-3039 
 Fax: 513/636-x453 
 ATTN: Joseph D. Fondacaro, Ph.D. 
  
 ARTICLE 9 – TERMINATION 
  

	9.1	Company may terminate this Agreement at any time by providing one (1) year’s written notice to CHRF. 

  

	9.2	In the event that Company should be in default of any of its obligations hereunder, CHRF may at its sole option: (a) terminate this Agreement or (b) convert the exclusive license
hereunder to a non-exclusive license. This option (a) or (b) of CHRF shall be exercised by written notice to Company specifying the nature of the and shall be effective thirty (30) days following receipt of said notice by Company unless Company
cures paid default prior to the expiration of said period of thirty (30) days. 

  

	9.3	Upon termination of this Agreement or conversion to a non-exclusive license as provided under Paragraphs 9.1 or 9.2, neither party shall be relieved of any obligations incurred
prior to such termination or conversion, and the obligations of the Parties under Articles 4 and 7 and Paragraphs 10.3 and 10.4 or any provisions which by their nature are intended to survive any such termination or conversion shall survive and
continue to be enforceable. 

  
 ARTICLE 10 -
MISCELLANEOUS 
  

	10.1	Company agrees to defend CHRF at Company’s cost and expense, and will indemnify and hold harmless CHRF from and against any and all losses, costs, damages, fees or expenses
arising out of or in connection with the manufacture, use, commercialization, marketing or sale by Company of any Product and/or Process hereunder. 

  

 5 

	10.2	Neither this Agreement nor any of the rights or obligations hereunder may be assigned by either party without the prior written consent of the other party. 

 

	10.3	It is understood that CHRF is subject to United States laws and regulations controlling the export of technical data, computer software, laboratory prototypes and other commodities,
and that its obligations hereunder are contingent on compliance with all applicable United States export laws and regulations. The transfer of certain technical data and/or commodities may require a license from the cognizant agency of the United
States Government and/or written assurances by Company that Company shall not export data or commodities to certain foreign countries without prior approval of such agency. CHRF neither represents nor warrants that a license shall not be required
nor that, if require, it shall be issued. In any event, Company specifically agrees not to export or re-export any information and/or technical data and/or products in violation of any applicable USA laws and/or regulations.

  

	10.4	This Agreement shall be construed under and interpreted under the Laws of the State of Ohio, USA, except that questions affecting the construction and effect of any Patent shall be
determined by the national law of the country in which the Patent has been granted. 

  

	10.5	In the event that either party is prevented from performing or is unable to perform any of its obligation under this Agreement due to any act of God, fire, casualty, flood, war,
strike, lockout, failure of public utilities, government regulation or the like, such party shall give notice to the other party in writing promptly, and thereupon the affected party’s performance shall be excused and the time for performance
shall be extended for the period of delay or inability to perform due to such occurrence. 

  

	10.6	The waiver by either party of a breach or default of any provisions of this Agreement by the other party must be in written form and signed by both parties, and shall not be
construed as a waiver of any succeeding breach of the same or any other provision. 

  

	10.7	This Agreement contains the frill understanding of the parties with respect to the subject matter hereof and supersedes all prior understandings and writings relating thereto.

  
 IN WITNESS WHEREOF, the parties hereto have caused this
Agreement to be executed by their properly and duly authorized officers or representatives as of the date first above written. 
  

			
	 CHILDREN’S HOSPITAL
 RESEARCH FOUNDATION
	 	 SYNTHETIC BLOOD
 INTERNATIONAL, INC.

		
	 /s/

	 	 /s/

	 Thomas F. Boat, M.D.
 Director
	 	 Robert W. Nicora
 President

		
	 02/27/01
 Date
	 	 02/28/01
 Date

  

 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]